Department of Surgery, Division of General Surgery, University of Washington/Fred Hutch Cancer Center, Seattle, WA, USA.
Department of Surgery, Division of Surgical Oncology, Atrium Health Wake Forest Baptist, Winston Salem, NC, USA.
Ann Surg Oncol. 2024 Aug;31(8):5361-5369. doi: 10.1245/s10434-024-15304-x. Epub 2024 May 3.
Over the last few decades, the role of cytoreductive surgery (CRS) with or without regional-based peritoneal therapies such as hyperthermic intraperitoneal chemotherapy (HIPEC) has evolved in the management of patients with peritoneal surface malignances (PSMs). Despite the benefit of CRS in improving oncologic outcomes, significant challenges remain in the treatment of patients with advanced PSMs, and the role of HIPEC continues to be questioned. Additionally, while there has been improvement in perioperative outcomes, long-term survival remains poor. As a result, there is much need to improve our understanding of the processes that drive tumor biology, thereby improving patient selection for various treatment approaches. Additionally, newer therapies are needed for patients who remain poor surgical candidates and who progress on systemic therapy. This article highlights recently published studies that we consider impactful in the care of patients with PSMs.
在过去的几十年中，细胞减灭术（CRS）联合或不联合区域性腹膜治疗（如腹腔内热化疗（HIPEC））在腹膜表面恶性肿瘤（PSM）患者的治疗中的作用不断发展。尽管 CRS 提高了肿瘤学治疗效果，但在治疗晚期 PSM 患者方面仍存在重大挑战，HIPEC 的作用也仍存在争议。此外，尽管围手术期结局有所改善，但长期生存率仍较低。因此，我们非常有必要深入了解推动肿瘤生物学发展的过程，从而改善各种治疗方法的患者选择。此外，对于那些仍然不适合手术且在系统治疗中进展的患者，需要新的治疗方法。本文重点介绍了我们认为对 PSM 患者治疗有影响的最新研究。
